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Abstract
Background: Stem cells or immune cells targeting the central nervous system (CNS) bear significant promises for
patients affected by CNS disorders. Brain or spinal cord delivery of therapeutic cells is limited by the blood-brain
barrier (BBB) which remains one of the recognized rate-limiting steps. Osmotic BBB disruption (BBBD) has been
shown to improve small molecule chemotherapy for brain tumors, but successful delivery of cells in conjunction
with BBBD has never been reported.
We have used a clinically relevant model (pig) of BBBD to attempt brain delivery of TALL-104, a human leukemic T
cell line. TALL-104 cells are potent tumor killers and have demonstrated potential for systemic tumor therapy. The
pig model used is analogous to the clinical BBBD procedure. Cells were injected in the carotid artery after labeling
with the MRI T1 contrast agent GdHPDO3A. Contrast CT scans were used to quantify BBBD and MRI was used to
detect Gd
++-loaded cells in the brain. Transcranial Doppler was used to monitor cerebral blood flow. EEG record-
ings were used to detect seizures. Immunocytochemical detection (Cresyl Violet, anti-human CD8 for TALL-104,
Evans Blue for BBB damage, GFAP and NEUN) was performed.
Results: At the concentration used TALL-104 cells were tolerated. Incomplete BBBD did not allow cell entry into
the brain. MRI scans at 24 and 48 hours post-injection allowed visualization of topographically segregated cells in
the hemisphere that underwent successful BBBD. Perivascular location of TALL-104 was confirmed in the BBBD
hemisphere by Cresyl violet and CD8 immunocytochemistry. No significant alteration in CBF or EEG activity was
recorded during cell injections.
Conclusions: Our data show that targeted CNS cell therapy requires blood-brain barrier disruption. MRI-detectable
cytotoxic anti-neoplastic cells can be forced to transverse the BBB and accumulate in the perivascular space. The
virtual absence of toxicity, the high anti-tumor activity of TALL-104, and the clinical feasibility of human osmotic
BBBD suggest that this approach may be adopted to treat brain or spinal cord tumors. In addition, BBBD may favor
CNS entry of other cells that normally lack CNS tropism.
Background
The brain is protected by physical and vascular barriers,
namely the skull and the blood-brain barrier (BBB). The
system of capillaries forming the human BBB has
approximately 20 m
2 of exchange surface with the brain
parenchyma, and is situated a few microns from neurons
and glial cells. In particular, the BBB controls the
exchange of nutrients, xenobiotics and serum-derived
factors between the systemic circulation and the brain,
thus contributing to brain homeostasis necessary for the
correct function of neurons [1]. At the cellular level, the
BBB is composed of endothelial cells and glia. Endothelial
cells are characterized by the presence of tight junctions,
minimal pinocytic vesicles, and lack of fenestrations.
The restrictive nature of the BBB prevents significant
penetration of many molecules and cells into the brain.
As a result, while protecting the brain from harmful
compounds, the BBB impedes or reduces access of
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any medium, provided the original work is properly cited.therapeutic molecules to the brain [2]. This restriction is
an important element contributing to our persistent
inability to treat many CNS diseases, spanning from epi-
lepsy to primary or metastatic brain tumors. The effi-
cacy of new or future molecular approaches or
exploiting of engineered cells, are and will be limited by
BBB penetration. Stem cells or immune cells targeting
the central nervous system bear significant promises for
patients affected by CNS disorders. Brain or spinal cord
delivery of therapeutic cells depends on a number of
factors, including endothelial adhesion molecules, dis-
ruption of tight junctions, and penetration across the
basal lamina surrounding the vessels [3]. Evidence sug-
gests that under normal conditions cell entry into the
brain occurs across larger vessels and venules [4-6].
However, to exert therapeutic actions it is desirable to
gain access to the neuropil located in the brain parench-
yma. Therefore, the usual pathway for immune traffick-
ing has to be extended to the BBB proper, e.g.,
capillaries surrounded by astrocytic endfeet and
pericytes.
Osmotic BBB disruption (BBBD) has been shown to
improve small molecule chemotherapy for brain tumors
[7] while its efficacy in promoting cell entry into the
brain is still unclear [8]. The BBBD procedure leads to
hemispheric disruption of the cerebrovasculature and
has been clinically demonstrated to enhance the delivery
of methotrexate to the brain [9] with tolerable side
effects [7]. While chemotherapy after BBBD has already
reached the clinical stage and demonstrated its thera-
peutic utility, animal models of BBBD are still viable
tools for further advancements of chemo- and cell ther-
apy. In particular, the pig model of BBBD is a faithful
replica of the clinical reality, including the imitation of
side effects [7,10,11].
Advances in our understanding of the cell and mole-
cular biology of neurological diseases have been made in
recent years. These advances have lead to the formula-
tion of novel therapeutic means including cytotoxic cell
therapy, such as lymphokine activated killer (LAK) cell,
tumor infiltrating lymphocytes (TIL) and the more
recent TALL-104 cells [12,13]. These therapies represent
a promising approach [12,14], but share a common
theme of low permeability through the BBB, impeding
the access to brain targets or tumor cells; in fact, suc-
cessful tumor invasion by these cells was only achieved
by direct CNS injection [13,15]. With these considera-
tions in mind, we decided to test the hypothesis that,
similar to methotrexate, therapeutic cell delivery to the
brain parenchyma requires blood-brain barrier disrup-
tion (BBBD). Since BBBD sporadically but reproducibly
leads to transient focal motor seizures in patients [7,10]
and animals [10,16] we also wished to assess whether
BBBD paired to cell injection bears additional side
effects. To ensure an immediate translation to human
studies, we used a large animal model of BBBD and
tools that are commonly employed in the clinical set-
ting. To exaggerate the possible morbidity of BBBD +
cell therapy, we used the cytotoxic human-derived
TALL-104 cells in slightly immunocompromised pigs.
Methods
Animal handling and anesthesia
Experimental research was performed according to the
International guidelines and the Cleveland Clinic
IACUC office. Experiments performed are included in
approved IACUC protocol. A total of eight 35 kg York-
shire pigs were placed under anesthesia using isofluor-
ane (1-1.5%). Anesthesia was induced by intramuscular
ketamine with the addition of xylazine (Rompun; 1-2
mg/kg) and atropine (0.02 mg/kg). Pigs were immuno-
suppressed with Cyclosporine-A to prevent possible
immunological reactions in response to the injection of
human-derived cells.
Blood-brain barrier disruption procedure
Under general anesthesia, pigs underwent MRI (coronal,
longitudinal T1 and perfusion) prior the hemispheric
BBB disruption procedures. Immediately after, pigs were
transferred to the operating room. In the supine posi-
tion, the femoral artery of the pig was cannulated and,
under fluoroscopic guidance, the internal carotid artery
catheterized. We performed angiography with a right
femoral artery cannulation and found that the swine
cerebral circulatory system demonstrated a plexus of
very small vessels (rete mirabile). The base of the brain
is perfused by the ascending pharyngeal artery and
reconstitutes downstream into the internal carotid
artery. Angiography was also performed to determine
the rate and volume of an injection to opacity and pos-
sible cross-filling of the contralateral (control) side.
Mannitol (25%) was then administered intra-arterially
via the catheter at a predetermined rate of 1-4 cc/sec
for 30 seconds, ranging from ineffective dosages (30 ml/
pig) to effective 90-120 ml/pig [7-10]. Procedures con-
ducted using low mannitol dosage or the contralateral
hemisphere in the effective BBBD procedures were used
as control.
Gd
++ -TALL-104 cells injection
Gd
++-loaded TALL-104 cells were provided by Abiogen-
Pharma S.p.a. in a sterile formulation ready for injection.
TALL-104 cells are of human origin and quality con-
trolled for the following: mycoplasma contamination,
bacterial contamination, fungal contamination, viral con-
tamination, antigenic profile, cytotoxic profile, genotype
and purity [17,18]. A small sample of cells was stained
with Trypan Blue to check the viability of the cells.
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filled with Gd
++-TALL-104 was scanned by MRI to con-
firm the presence of intracellular contrast. Intra-arterial
TALL-104 cells were infused immediately after BBBD
(7-8 × 10
9 in 20 ml of sterile saline) The number of
cells was chosen based on previous studies conducted in
rodents and ongoing clinical trials for the treatment of
systemic tumors [19-22]. Electroencephalography (EEG)
and trans-cranial Doppler (TCD) were performed during
each procedure. A second MRI was performed after the
BBBD procedures to evaluate the distribution of Gd
+
+-TALL-104 in the brain.
Electroencephalography
The following equipment was utilized to collect EEG data
during the procedures: Nihon Kohden EEG System
(Nihon Kohden JAPAN) Nihon Kohden Neurofax EEG
9000 Version 5-72 running on a WIndows XP platform
using DELL Optiplex GL280. A non-cephalic reference
was utilized for comparison. Tracings were collected on a
Nihon Kohden JE910-A jackbox, using sterile stainless
steel subdermal needle electrodes (13 × 0.40 mm with 0.5
× 27 Gauge) manufactured by Axon Systems Hauppage
NY. The system was electrically isolated from the pig and
the equipment used in performing angiographic proce-
dures. Diadem (National Instrument, USA) was used for
joint-time frequency analysis of electrical signals.
Trans-cranial Doppler
PMD150transcranial Doppler (Spencer Technologies,
Seattle, WA) was used to monitor cerebral blood flow
using power M-mode Doppler (PMD). PMD is a format
for presenting Doppler data which is in the style of tra-
ditional motion mode imaging (depth from the probe
on the vertical axis and time on the horizontal axis), but
shows power of the reflected Doppler signature over
depth instead of simple gray scale tissue reflection
amplitude. TCD probes were fixed on the head of the
pig on the orbital and in the temporal bones.
Histology and Immunohistochemistry
At the end of the BBBD procedure, five pigs were per-
fused with Evans Blue (2%, 4 ml/Kg) to allow histologi-
cal evaluationn of BBBD. At the end of each experiment
the brain was removed from the skull and formalin
fixed. Parenchymal extravasate of Evans Blue was first
assessed by visual inspection. Histological and immuno-
histochemical (IHC) staining were then performed from
blocks of parietal and temporal regions correspondent
to the territory supplied by the internal carotid artery.
For histological studies, sections (30-35 μm) stained
with 1% Cresyl violet (CV) for cytoarchitectural analysis
and presence of gross cellular extravasates in correspon-
dence of vessels. Free floating sections were stained with
anti-human CD8 to detect human TALL-104. We used:
polyclonal anti-human CD8 (Ab 4055, 1:100, Abcam);
monoclonal anti-GFAP (G 3893; 1:100, Sigma, Saint
Louis, Missouri, USA); NEUN (MAB 377, 1:500, Chemi-
con) Secondary antibodies: Texas red affinipure donkey
anti-mouse IgG (1:100 Jackson Laboratories Inc., West
Grove, PA, USA), and Fluorescein isothiocyanate
(FITC)-conjugated affinipure donkey anti-rabbit IgG
(1:100, Jackson Laboratories Inc., West Grove, PA,
USA). Autofluorescence was blocked with Sudan black
B. Sections were analyzed by confocal microscopy.
Cell quantification
Twenty seven slices from each brain hemisphere (tem-
poral lobe) were used to quantify cellular extravasation.
Pictures were taken using a bright field microscope (400
× 600 pixels/inch). Pictures were imported into Adobe
Photoshop 7.0 and transformed into a grayscale image.
Images were then processed using Phoretix 2D for cell
quantification (spot detection). Sensitivity and size of
signal was kept constant and controlled throughout out
the analysis.
Statistical analysis
We used Origin 7.0 (Origin Lab, Northampton, MA,
USA) and Jump 7.0 (SAS) software. Shapiro-Wilk test
was used to evaluate the normal distribution of the data.
Data are indicated as mean ± SEM. Student t-test was
used for direct comparison of two populations of data. p
< 0.05 was considered statistically significant.
Results
For the experiments described herein, we used a total of
8 pigs. Animals underwent intracarotid (ICA) injection
of Gd
++-TALL-104 after BBBD (Figure 1A-B). After a
preliminary pre-operative MRI scan and following
anesthesia induction, we first tested the localization of
the tip of the catheter (Figure 1 C1) by iodinated con-
trast injection. Angiography was also used to determine
the extent of contralateral diffusion of contrast, as well
as to visualize the extent of venous loading. Hemispheric
opening of the BBB was confirmed by Evan’s Blue stain-
ing (Figure 1 C2). Immediately prior to the actual injec-
tion, cells were prepared under sterile conditions and
counted. Cells were tested for vitality (Trypan Blue, Fig-
ure 1D) and capacity to retain the radiological marker
Gd
++ (Figure 1E).
Hyperosmotic mannitol was injected into the ICA as
described in the Methods section. Immediately after Gd
++-
TALL-104 cells were injected (velocity = 1 ml/sec) using
the same catheter. Throughout the procedures, we moni-
tored cerebral blood flow, EEG activity and vital signs.
We used several independent methods to evaluate the
toxicity of the cell injection procedure. At the
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were well tolerated. Figure 2A-B shows examples of
MRI scans and gross and anatomic observations in ani-
mals injected with a low, ineffective dosage of mannitol
(1 ml/sec, 30 seconds) followed by Gd
++-TALL104.
Note that no discernable MRI changes were seen. MRI
appearances of pre-procedure and post-procedure scans
were identical. This was further confirmed by gross ana-
tomic observations of Evans Blue extravasation (Figure 2
C-F). We tested the contralateral brain by histological
and gross anatomical means. In all cases, the two hemi-
spheres were found to be virtually identical (Figure 2 C-
F). Another functional parameter that was assessed
following the procedure was perfusion-weighed imaging
to unveil possible infractions or altered brain hemody-
namics after the procedure. These perfusion maps were
then analyzed and compared to normal (pre-BBBD)
imaging as shown in Figure 2G. We never observed any
change in perfusion patterns in the animals tested.
Sagittal MRI scans were also performed to rule brain or
cervical cord damage (Figure 2H).
In 1/3 of the procedures an excellent opening of the
BBB was achieved when using mannitol 4 ml/sec, 30
seconds, as judged by the extravasation of Evans Blue
and comparison with the contralateral hemisphere
(Figure 3A-E). In these procedures, the extent of leakage
was comparable to what was previously reported [10]. In
particular, we confirmed that in the BBBD hemisphere a
faint overall leakage pattern was punctuated by spots of
more pronounced dye extravasation (Figure 3B-E).
These spots were comparable to the pre-sacrifice
Figure 1 Schematic representation of the surgical procedure
and quality control of Gd
++-TALL-104 cells. A) Experimental
steps common to all the experiments. BBB disruption (BBBD) was
performed after baseline MRI. Continuous electroencephalography
(EEG) and trans-cranial Doppler (TCD) recordings were performed.
MRI scans were performed before and 48 hours after the
procedures. B) Catheter was placed in the femoral artery and
angiographically guided to the ICA at the base of the brain. C1)
Localization of the tip of the catheter and angiographic exploration.
Note the extent of contrast diffusion to the hemisphere
correspondent to the ICA cannulated and a modest spread to the
contralateral side. Note also the venous return after contrast
injection. C2) Successful BBBD lead to hemispheric leakage of Evan’s
Blue in the brain parenchyma. Note the negligible amount of blue
signal in the contralateral side. D) Cell vitality was demonstrated by
lack of Trypan Blue penetration. E) MRI scans (T1) confirmed that
TALL-104 cells retain Gd
++.
Figure 2 Lack of BBB opening can be detected radiologically
or histologically. A-B) Example of an ineffective BBBD procedure.
A low ineffective concentration of mannitol was used as control
(non-BBBD, see methods). Radiological (MRI, T1) scans were similar
before and after the BBBD procedure. Note the lack of Gd
++ signal
in the scans taken after BBBD procedure, suggesting lack of cellular
brain penetration. C-F) Ex-vivo, the absence of Evans Blue brain
leakage further confirmed the lack of BBB opening in this animal.
BBBD and contralateral sides were virtually identical. G-H) Perfusion
scans and sagittal T1 sequences were taken after BBBD procedures
to rule out the presence of gross anatomical alteration associated
with the procedure.
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++
loaded cells immediately after mannitol. Note that the
approximate size and location of extravasations mea-
sured by Evan Blue were similar to what was seen in
vivo (Figure 3G-I). Note also the lack of extravasation
and Gd
++ signal in the contralateral side. In the remain-
ing 2/3 of procedures, the extent of Evans blue extrava-
sation was limited to a few sites of extravasation and
was similar to control procedures shown in Figure 2.
The results so far presented confirmed that BBBD does
not always result in maximal “opening” of the BBB and
that successful openings are characterized by a patchy
distribution of leakage spots [10].
Brains were analyzed microscopically and the extent of
cellular extravasation quantified by traditional histologi-
cal means (Cresyl Violet) or immunostaining (human
anti-CD8). Figure 4 shows an example of histological
appearance of brain sections from an animal where BBB
disruption was not induced; this was also previously
quantified by contrast-enhanced MRI and post-mortem
histological evaluation of Evan Blue (Figure 2). Note
that the MRI test was performed 24 hours after BBBD
while the histology was done 48 hours after the proce-
dure. Under conditions of absent BBB disruption, cell
extravasation was confined to the Virchow-Robin space
surrounding large penetrating pial vessels or in
Figure 3 Evaluation of a successful blood-brain barrier
disruption. A-B) Note Evans Blue leakages in the parietal BBBD
hemisphere compared to the correspondent contralateral areas (C-
D). B and E show additional details of parenchymal dye
extravasations (arrowheads). (F-I) Histological findings were
confirmed by MRI (T1). Serial images show Gd
++- positive signals in
the same regions where Evans Blue leakage was detected
(arrowheads).
Figure 4 Lack of microscopic evidence of cell brain
extravasations after modest BBBD procedures. A-C) When BBB
disruption was not induced (see also Figure 2), cellular extravasation
(as detected by Cresyl Violet) was limited to the Virchow-Robin
space or to the proximity of superficial meninges. Modest and
localized Gd
++extravasation was observed in the same regions. D-H)
Cresyl Violet staining showed that parenchymal vessels were
generally devoid of cellular extravasates. The reddish stain is
indicative of hemoglobin accumulations in erythrocytes. Arrowhead
indicates vessel in both BBBD and contralateral hemispheres. I)
Small clusters of cells were infrequently observed in the proximity
of vessels (asterisk).
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3D-H) while isolated, small clusters of cells were infre-
quently observed (asterisk in Figure 2I).
These measurements were repeated in pigs where a
successful BBB opening was achieved (Figure 5). Several
spots of cellular extravasates were observed in associa-
tion with pial and parenchymal vessels in the BBBD
hemisphere (Figure 5A, C) Figure 5E shows the quantifi-
cation of the number of vessels associated with cellular
extravasates. Note that the contralateral hemisphere is
used as internal control for the BBBD side (Figure 5B,
D). Thus, little amount of cells was observed perivascu-
larly in the contralateral side (Figure 5, panel F). These
data were confirmed both radiologically (Figure 3) and
histologically (Figure 5). In spite of the fact that
extravasation was obvious in these animals both radiolo-
gically and histologically, most of the cells were confined
to the perivascular space and only a small percentage of
cells was found in the brain parenchyma (Figure 5F)
We performed immunocytochemical analysis to detect
human CD8-positive cells to unequivocally determine
t h ec e l lt y p ei ne x t r a v a s a t e s( T A L L - 1 0 4 vs. autologous
white blood cells). The evaluation was conducted in ani-
mals where the BBB was breached successfully (Figure
6I-P) as well as in those where BBBD was not induced
(Figure 6 A-H). Cell extravasates seen histologically
comprised invariably of CD8
+ cells. Lack of BBB open-
ing resulted in negligible number of CD8
+ cells in the
perivascular space (Figure 6A, C-D). CD8
+ cells were
confined within the vascular bed (Figure 6C, E-G). After
Figure 5 Pattern of cell brain extravasations after successful
BBBD. A, C) Accumulation of cells in the proximity of vessels was
observed in the BBBD hemisphere. Groups of cells were detected in
the sections analyzed (See Methods for Details). B, D) Conversely,
fewer cells were detected in the contralateral non-BBBD
hemisphere. E-F) A significant number of vessels was associated
with cellular extravasates. These vessels were mostly confined to the
BBBD hemisphere (F). Cell extravasates were distributed in the
immediate proximity of the disrupted vessels (perivascular
compartment, red bar in F), while negligible amounts were
measured in the parenchyma (not shown).
Figure 6 Immunohistochemical characterization of the cellular
extravasates. Anti-human CD8 antibody was used to identify TALL-
104 cells within the cellular extravasates. A-D) Negligible amounts of
CD8 positive cells were detected in the perivascular space when BBB
was not breached (see also Figures 2 and 4). Arrowheads in B and H
show examples of the rare extravasated cells. (E-G) Note that CD8
immunoreactivity was mostly confined in the intravascular space. I-P)
Brain sections obtained from successful BBBD procedures display
elevated anti-CD8 immunoreactivity in correspondence of
perivascular aggregates of cells (arrowheads). See also Figure 3 and 5.
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found in correspondence of vessels (Figure 6I-P).
The neurophysiological effects of BBBD and cell injec-
tion on cerebral function were measured by EEG (Figure
7). A joint time FFT frequency plot was constructed to
demonstrate even small changes in EEG frequency
occurring during of after BBBD. In all experiments,
mannitol injection caused a transient “loss” of EEG sig-
nal, presumably due to the rapid passage of high osmo-
larity blood through the region of recording[10]. This
electrical silence lasted a few seconds to one minute and
was also reflected by the change in TCD signal (Figure
8). In general, EEG recordings were unremarkable up to
one hour post-BBBD, at which point the animal was
weaned off respirator and anesthesia. No frank
behavioral or electrographic seizures were observed in
the animals tested. When maximal BBB disruption was
achieved, changes in EEG frequency were observed
(Figure 7). These changes consisted of increased signal
intensity in the 5-10 Hz range (Figure 7B).
While steady-state (48 hrs) post-operative changes in
CBF were monitored by perfusion MRI, the acute
cerebrovascular safety of the procedure was confirmed
by transcranial Doppler monitoring (Figure 8). Cerebral
blood flow velocity was slightly increased in the immedi-
ate period after blood-brain barrier disruption (Figure
8E). Within 10 minutes after the procedure, CBF values
returned to pre-BBBD levels. Note that mannitol injec-
tion caused a significant perturbation of the signal, pre-
sumably due to the altered acoustical properties of
hyperosmotic solutions. This change did not, however,
interfere with measurements of Doppler velocity, but
temporally corresponded to the apparent loss of EEG
signal.
Discussion
To our knowledge, this is the first demonstration that
MRI-detectable cytotoxic cells with proven anti-neoplas-
tic activity can transverse the BBB by clinically realistic
means. Our data show that targeted CNS cell therapy
requires BBB disruption. The virtual absence of toxicity,
the high anti-tumor activity of TALL-104, and the clini-
cal feasibility of human osmotic BBBD suggest that this
approach may be used to treat brain or spinal cord
tumors. In addition, BBBD may favor CNS entry of
other cells that normally lack CNS tropism.
Cell trafficking at the BBB
It is generally assumed that trans-BBB trafficking of
white blood cells is a common and frequent occurrence
(for a critical discussion see [5]). Our results in contrast
propose that trans-BBB penetration of cells is a rela-
tively infrequent event and require BBB opening. The
results showed that even when the BBB is breached, cell
extravasation in the brain parenchyma is not widespread
but mostly confined to the perivascular space. No signif-
icant cell entry was observed in non-BBBD procedures
(Figures 2 and 4) or in the contralateral side of BBBD
procedures (Figures 3 and 5).
It is, however, well accepted that antigen plays a major
role in trafficking of cells to the brain. Non specific CD8
T cells which has not been activated through their T
cell receptor will not cross the BBB, while their counter-
parts where antigen presentation and subsequent activa-
tion has occurred, will. We may therefore conclude that
in our experiments TALL-104 cells were not capable of
greatly entering the CNS because of lack of prior anti-
gen activation. This also implies that the presence of
tumor cells in the brain could greatly increase cell deliv-
ery. Cell trafficking in brain with an intact or only
slightly breached BBB, was limited to the subdural
regions. Trials with tumor-bearing animals will unveil
whether these levels of extravasated cells after BBBD are
sufficient to exert toxic activity against brain neoplasms.
There are several issues that may have confounded the
interpretation of our results. The possibility exists that
Figure 7 EEG monitoring during BBBD and cell injection. A)
EEG recordings revealed abnormal neuronal activity after a
successful BBBD. However, no frank seizures were observed in these
animals. The injection of cells did not exacerbate the EEG alterations
provoked by the BBBD procedure. B) A joint time FFT frequency
plot reveals the changes in EEG frequency over time and in
relationship to BBBD. Note the increase in 5-10 Hz frequencies after
mannitol injections and the increase in spike amplitude (color
coded).
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Cerebral blood flow velocity was slightly increased immediately after BBBD (See Text for Details).
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media is not sufficient to disrupt tight junctions. This is
a reasonable concern, given the fact that we and others
have shown that mannitol-induced BBBD causes vari-
able extent of “opening” [7,10]. This, however, was a
controlled variable in our study, since we measured pro-
nounced extravasation of Evans Blue (and FITC-labeled
albumin [10]). When the extent of clinical or experi-
mental BBBD was measured radiologically, a full range
of efficacy was shown, from nil to excellent [7,10]; in
addition, the clinical response to chemotherapy was
highly suggestive of improved drug delivery of metho-
trexate to the brain. Thus, it appears that leakage of
small molecules (e.g., dyes) or dye-bound protein does
not immediately translate into cell extravasation in the
parenchyma. This was indirectly confirmed by numerous
studies where extravasation of albumin, immunoglobu-
lins or other protein was observed in brain regions with
little cell extravasation beyond the perivascular space
[23-27].
Clinical significance and translation
The safety of the combined approach used (cytotoxic
cells and blood-brain barrier disruption) suggests that
this is a viable means for targeted cell delivery to the
brain. Our previous experiments have shown that suc-
cessful BBBD promote seizures [10]. Based on this we
cannot therefore speculate on whether or not T cell
entry is necessary for seizure induction. However, the
delay between injection of mannitol, BBB disruption and
seizure generation (few minutes) argues against a
sophisticated cell-to-cell interaction or immunological
release of antibodies. Further experiments are necessary
to clarify the role, if any, of specific cell sub-types in the
generational seizures. It does remain, however, possible,
that epilepsy but not seizures are maintained by WBCs
which enter the brain. These investigations were beyond
the scope of our study but clearly bare clinical
significance.
Our previous experiments have shown that in patients
BBBD is variable even when the surgical team remains
the same and the protocols are respected [7,10]. How-
ever, in these human trials as well as in the experiment
presented here we did not use sham - operated animals.
This is due in part to the fact that large animal experi-
ments are extremely complicated and approval for sham
procedures are difficult to obtain; however, there is also
scientific supports that make these experiments
unnecessary. In fact, we and others have shown that
BBBD by intracarotid injection does not affect the con-
tralateral side. In other words, the contralateral brain
acts as a control [7,10]. The cell extravasation data
s h o w ni nF i g u r e5s h o wap r e f e r e n c ef o rt h ed i s r u p t e d
hemisphere thus confirming that BBBD allows better
extravasation of the cells. This is further supported by
the fact that seizures induced by BBBD invariably origi-
nate in the disrupted hemisphere and have motor com-
ponent spread to the contralateral side of the body [10].
Our experiments may show promise for the treatment
of primary or metastatic brain tumors. In vitro,T A L L -
104 cells show significant cytotoxic activity against
human glioblastoma cell lines (U-87 MG, U-251 MG,
and A1690), the medulloblastoma cell lines DAOY,
D283 Med, and D341 and the epidermoid cancer cell
line A431. TALL-104 cells also cause lysis of human-
derived brain tumor cells, sparing normal brain cells
[17,18]. To date, only one report showed the safety and
the potential therapeutic effects of TALL-104 cells in
reducing brain tumor burden [17,18]. The authors
investigated the efficacy of TALL-104 cells in reducing a
human A431 carcinoma implanted in brain. However,
TALL-104 cells were directly administered into the
brain (intraventricularly). Of relevance is the fact that
no adverse reactions (e.g., allergic encephalitic) were
triggered by TALL-104 brain injection [17,18]. Interest-
ingly, in rodents, TALL-104 cells did not penetrate the
brain when injected intravenously and without manipu-
lation of the BBB [28]. TALL-104 cells were well toler-
ated by patients enrolled in two phase I clinical trial for
systemic cancer at the doses and regimen tested [22].
There are numerous other cell lines that may be used
for cellular therapy of brain tumors, and the example
shown here simply addressed the feasibility and safety of
this approach in an animal model that closely mimics
the clinical reality.
Conclusions
Our data show that brain penetration of peripherally cir-
culating cells requires BBB disruption and it is limited
to the immediate perivascular space. Specifically, MRI-
detectable cells can be forced to transverse the BBB
using clinically realistic means.
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